Dr. Scott Tagawa reviews the PSMAddition trial, showing that adding lutetium PSMA-617 to ADT and ARPI improves progression-free outcomes but increases toxicity. Despite this, patient-reported outcomes suggest quality of life remains largely comparable after the initial treatment period, supporting its potential frontline use in eligible patients. He also emphasizes the complexity of interpreting PSMA PET data in this setting and highlights the growing need for better biomarkers to guide treatment selection.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
